Phase IIIb study to evaluate immunogenicity and safety of GlaxoSmithKline Biologicals' HPV vaccine 580299 when administered in healthy adolescent and adult female subjects.

Trial Profile

Phase IIIb study to evaluate immunogenicity and safety of GlaxoSmithKline Biologicals' HPV vaccine 580299 when administered in healthy adolescent and adult female subjects.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; AS04B
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 28 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 May 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
    • 01 Sep 2009 Planned end date changed from 1 Jul 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top